Its net profit stood at RON87 million at the end of September 2025, compared to RON73 million in the same period of 2024.
In the first nine months of 2025, Biofarm S.A. placed 2nd and 1st on the Consumer Healthcare (CHC) segment in terms of the number of units sold and 7th place in value, as compared to the purchase price of pharmacies. Biofarm is the market leader by volume in the reference categories of six of its brands: Bixtonim, Colebil, Triferment, Extravalerianic, Carmol and Carbocit, per its financial statement.
Biofarm S.A. owns two drug factories in Bucharest and one product testing and development unit, and its portfolio of over 100 products covers the most important therapeutic areas in the Consumer Healthcare division (digestive & metabolic, respiratory & ENT, cardiovascular & circulatory, nervous system, vitamins).